Longevity Biotech (LBT) has been awarded a Phase I SBIR Contract from the National Heart, Lung, and Blood Institute (NHLBI) to further the development of the 5A apoA-I mimetic peptide program for the treatment of severe asthma.    The overall goal of this project is to prepare an inhalational 5A apoA-I mimetic peptide that will become the subject of a future Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) initially focused on patients who do not ...